Losing Lyumjev: how the system let down patients
Too much, too little, at the wrong time: Zucara’s ZT-01 and the glucagon problem in type 1 diabetes

Zucara’s ZT-01: what could taking the brake off glucagon do?

23/09/2026 admin 0

ZT-01 aims to restore glucagon counterregulation during hypoglycaemia. But type 1 diabetes already produces glucagon at the wrong time — and Zucara’s own human data show SSTR2 blockade raises glucagon, glucose and insulin requirements during euglycaemia. What will the trials tell us about its longer term effects?

Bolt AI into your loop and you might just have become a medical device manufacturer

28/08/2026 admin 0

Embedded AI is starting to appear in open source AID systems, offered as copy and paste, bring your own key, or a service the project runs. A year of measuring these models says the clinical risk is much the same in all three. The regulatory position is not, and the intuition about which is safest runs backwards.

The world’s first digital endocrinologist, and why you should keep your money.